Charles Schwab Investment Management Inc. grew its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 4.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 377,900 shares of the biotechnology company's stock after purchasing an additional 14,521 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.67% of Repligen worth $54,395,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of RGEN. Champlain Investment Partners LLC increased its holdings in Repligen by 149.0% in the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company's stock valued at $211,464,000 after purchasing an additional 850,345 shares in the last quarter. Conestoga Capital Advisors LLC boosted its position in shares of Repligen by 0.7% in the fourth quarter. Conestoga Capital Advisors LLC now owns 947,582 shares of the biotechnology company's stock worth $136,395,000 after buying an additional 6,872 shares during the period. Thrivent Financial for Lutherans raised its holdings in shares of Repligen by 6.1% during the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company's stock valued at $95,037,000 after buying an additional 36,773 shares during the period. DF Dent & Co. Inc. raised its holdings in shares of Repligen by 31.0% during the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company's stock valued at $87,852,000 after buying an additional 139,615 shares during the period. Finally, New York State Common Retirement Fund lifted its position in Repligen by 2.5% during the 4th quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company's stock worth $83,693,000 after acquiring an additional 14,398 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.
Repligen Stock Performance
Shares of NASDAQ RGEN traded up $2.19 during trading on Monday, reaching $152.81. The stock had a trading volume of 481,613 shares, compared to its average volume of 644,089. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The stock has a market cap of $8.56 billion, a PE ratio of -299.63, a P/E/G ratio of 4.54 and a beta of 0.95. Repligen Co. has a one year low of $113.50 and a one year high of $200.23. The firm's 50 day moving average price is $157.19 and its two-hundred day moving average price is $148.52.
Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm had revenue of $167.55 million during the quarter, compared to analyst estimates of $167.58 million. On average, research analysts forecast that Repligen Co. will post 1.72 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on RGEN. Royal Bank of Canada boosted their target price on shares of Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research report on Friday, February 21st. Canaccord Genuity Group initiated coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective on the stock. TD Cowen assumed coverage on Repligen in a research note on Monday, February 10th. They set a "buy" rating and a $200.00 target price for the company. JPMorgan Chase & Co. boosted their price target on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research note on Friday, February 21st. Finally, StockNews.com lowered Repligen from a "hold" rating to a "sell" rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Repligen has an average rating of "Moderate Buy" and a consensus price target of $181.00.
View Our Latest Stock Report on RGEN
Repligen Company Profile
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Read More
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
